Novel human antibody therapeutics: the age of the Umabs.
Monoclonal antibodies represent a major and increasingly important category of biotechnology products for the treatment of human diseases. The state-of-the-art of antibody technology has evolved to the point where therapeutic monoclonal antibodies, that are practically indistinguishable from antibodies induced in humans, are routinely generated. We depict how our science-based approach can be used to further improve the efficacy of antibody therapeutics, illustrated by the development of three monoclonal antibodies for various cancer indications: zanolimumab (directed against CD4), ofatumumab (directed against CD20) and zalutumumab (directed against epidermal growth factor receptor).
Ruuls
Sigrid R
SR
Genmab, Yalelaan 60, 3584 CM Utrecht, The Netherlands.
Lammerts van Bueren
Jeroen J
JJ
van de Winkel
Jan G J
JG
Parren
Paul W H I
PW
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D008954:Models, Biological; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C546618:zalutumumab; C520522:zanolimumab; C527517:ofatumumab